Murine Modeling of Myeloproliferative Neoplasms

Karie Chen; Alan H Shih

doi:10.1016/j.hoc.2020.11.007

Murine Modeling of Myeloproliferative Neoplasms

Hematol Oncol Clin North Am. 2021 Apr;35(2):253-265. doi: 10.1016/j.hoc.2020.11.007. Epub 2020 Dec 30.

Authors

Karie Chen¹, Alan H Shih²

Affiliations

¹ Department of Medicine, Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1079, New York, NY 10029, USA.
² Department of Medicine, Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1079, New York, NY 10029, USA. Electronic address: alan.shih@mssm.edu.

PMID: 33641867
DOI: 10.1016/j.hoc.2020.11.007

Abstract

Myeloproliferative neoplasms, such as polycythemia vera, essential thrombocythemia, and primary myelofibrosis, are bone marrow disorders that result in the overproduction of mature clonal myeloid elements. Identification of recurrent genetic mutations has been described and aid in diagnosis and prognostic determination. Mouse models of these mutations have confirmed the biologic significance of these mutations in myeloproliferative neoplasm disease biology and provided greater insights on the pathways that are dysregulated with each mutation. The models are useful tools that have led to preclinical testing and provided data as validation for future myeloproliferative neoplasm clinical trials.

Keywords: CALR; Epigenetics; JAK2; MPL; Mouse model; Myeloproliferative neoplasm; Preclinical trial.

Publication types

Research Support, N.I.H., Extramural
Review

MeSH terms

Animals
Disease Models, Animal*
Mice
Mutation
Myeloproliferative Disorders* / diagnosis
Myeloproliferative Disorders* / genetics
Neoplasms* / diagnosis
Neoplasms* / genetics

Grants and funding

K08 CA181507/CA/NCI NIH HHS/United States